Sun Pharma Share Price Target 2026, 2027, 2028, 2029, 2030

Sun Pharma share price today

Sun Pharmaceutical (NSE: SUNPHARMA) is India’s largest drugmaker, and for the past few years it has been quietly changing what kind of company it is. The old Sun sold generics by the tonne and lived with generic-industry economics. The new Sun earns an increasing share of profit from global specialty brands — Ilumya in psoriasis, Cequa in dry eye, Leqselvi in alopecia — products with patents, pricing power and 30% operating margins attached.

At 37.6× earnings, the market has noticed. The question this article answers is what that price already assumes, and what is left on the table for a buyer at ₹1,964.

From volume to value

Specialty is the whole thesis. Generic drugs are a treadmill: price erosion every year, offset only by new launches. Specialty brands compound instead — a dermatology franchise grows for a decade. Sun’s specialty revenue has become the swing factor in its mix, and it is why operating margin sits near 30% while five-year profit growth (16.7% CAGR) has outrun sales growth (11.8%).

The watch-items: US FDA inspections (the perennial Indian pharma risk), the pace of specialty ramp against R&D spend, and a promoter pledge of 1.65% — small, but worth knowing exists.

The numbers

From our research universe snapshot (5 Aug 2026):

Metric	Value
Market cap	₹4,74,492 Cr
P/E (TTM)	37.6
EV/EBITDA	23.3
Operating margin	29.8%
ROE / ROCE	16.0% / 20.5%
Debt to equity	0.06
Sales CAGR (5y)	11.8%
Profit CAGR (5y)	16.8%
Promoter holding	54.5% (1.65% pledged)
EPS (TTM)	₹52.3

Sun Pharma share price target 2026 to 2030

EPS base ₹52.3 (TTM). Bear: specialty ramp stalls and an FDA setback bites — 8% growth, multiple compresses to 26×. Base: specialty keeps mixing margins up — 13% growth at 32×. Bull: a specialty asset breaks out globally — 17% growth at 38×.

Year	Bear (26×, +8%)	Base (32×, +13%)	Bull (38×, +17%)
2026	₹1,470	₹1,890	₹2,325
2027	₹1,585	₹2,135	₹2,720
2028	₹1,715	₹2,415	₹3,185
2029	₹1,850	₹2,730	₹3,725
2030	₹2,000	₹3,085	₹4,360

Base case from ₹1,964: ≈ +57% over four and a half years plus dividends — solid rather than spectacular, which is what “quality fairly priced” means. The bear case is nearly flat, a decent floor for a market leader. The upside case needs specialty to surprise; that optionality is the real reason to own Sun over a cheaper generic-only peer.

Reasons to own Sun Pharma (at the right price)

1. India’s #1 pharma company by scale — and scale in pharma buys distribution, manufacturing depth and regulatory muscle.
2. Specialty portfolio changes the earnings quality — brands, not commodity generics, now drive the mix.
3. ~30% OPM with near-zero debt (D/E 0.06).
4. 20.5% ROCE, improving with the mix.
5. A domestic branded business that compounds quietly beneath the US story.

The risks: FDA inspection outcomes can hit any plant, specialty R&D is expensive with binary outcomes, and 37× leaves little room for a flat year.

Should you buy at the current price?

The live buy range below is for members — the accumulation zone where the base case pays properly.

FAQ

What is the Sun Pharma share price target for 2030? Base case ≈ ₹3,085 (32× on 13% compounded growth), bear ≈ ₹2,000, bull ≈ ₹4,360. Arithmetic above.

Why does Sun Pharma trade richer than other Indian pharma companies? The specialty-brand mix. Patented dermatology and ophthalmology franchises earn better, steadier margins than commodity generics, and the market pays up for that quality.

What is Sun Pharma’s biggest risk? US FDA compliance — an adverse inspection at a key plant can interrupt supply and sentiment simultaneously.

When are Sun Pharma’s next results? Track the exact date on our results calendar.

---

This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.